Review by Booklist Review
Perhaps there is no one better suited to putting a story of medical and scientific research into context than award-winning journalist Palfreman. That he brings his prodigious analytical and reportorial skills to the task of describing the latest discoveries about the baffling neurodegenerative disease named for a nineteenth-century surgeon makes Parkinson's disease the stuff of page-turning enlightenment. And that's for readers whose life is unaffected by it. For those diagnosed with the disease, the so-called Parkies, and their families and friends, it ought to prove downright riveting. After devoting a few pages to the history and discovery of Parkinson's, first observed in records dating nearly from the dawn of recorded history, Palfreman, in subsequent chapters, builds, block-by-block, a structure that any layperson can understand. His descriptions of the myriad approaches to the search for a cure range from the pharmaceutical to surgical to therapeutic and are just thorough enough. The information is clear, careful, dotted with the personal experiences of Palfreman and his fellow Parkies (including actor Michael J. Fox), and hopeful.--Chavez, Donna Copyright 2015 Booklist
From Booklist, Copyright (c) American Library Association. Used with permission.
Review by Publisher's Weekly Review
Award-winning journalist Palfreman's fast-paced, captivating, and crisp narrative of patients, doctors, and researchers is part scientific investigation, part medical detective story, and part memoir, and it opens wide a window into the world of Parkinson's. He introduces readers to James Parkinson, who in 1817 offered the first clinical description of the disease; Jean-Martin Charcot, who accurately described the signs and symptoms of what appeared to be a movement disorder; Constantin Tretiakoff, who demonstrated that the disease was caused by damage to the substantia nigra portion of the brain; and Frederick Lewy, who discovered the pathological hallmarks of Parkinson's. Palfreman, who was diagnosed with the disease during his research, investigates drug therapies, such as the routine L-dopa therapy initiated in the 1960s and still used frequently today, and experimental drugs such as NPT088, which has yet to be approved by the FDA. There are more than seven million Parkinson's sufferers worldwide and Palfreman shares some of their stories, including that of dancer Pam Quinn, who has learned to "trick" her symptoms and teaches her methods to other Parkinson's patients. He reminds readers that a diagnosis of Parkinson's is a life sentence, but Palfreman remains optimistic about what new discoveries may be able to offer Parkinson's patients. Agent: Kneerim, Williams, & Bloom. (Sept.) © Copyright PWxyz, LLC. All rights reserved.
(c) Copyright PWxyz, LLC. All rights reserved
Review by Library Journal Review
The general public may think they know what Parkinson's disease is-something that mainly old people get and that causes tremors-but the reality of the condition is more complex and confounding, explains science journalist -Palfreman (KEZI Distinguished Professor of Broadcast Journalism, Univ. of Oregon; The Case of the Frozen Addicts), himself a sufferer. Some forms of the disease are inherited and others are environmentally caused; there is no definitive test that can be performed on living patients, and upon autopsy, some are found not to have had Parkinson's at all; and the disease has lately been recognized as much more than a motor disorder. Palfreman describes heroic measures by scientists, not to mention their animal and human subjects, in the effort to find a cure or a way to halt symptoms-everything from experimental surgeries to using viruses to deliver treatment. Sprinkled throughout are doctor, researcher, and patient accounts and the author's own story and opinions, which create a resource that can help those affected to learn more about the disease, understand better how their medication works and was developed, and deal with symptoms. A section on a dancer who has Parkinson's is particularly helpful, offering tips on how to move more easily. The language can get quite scientific, but patients who are familiar with popular science works will have no problem. -VERDICT Solid research, engagingly presented; a great resource for patients and their families.-Henrietta Verma, Library Journal © Copyright 2015. Library Journals LLC, a wholly owned subsidiary of Media Source, Inc. No redistribution permitted.
(c) Copyright Library Journals LLC, a wholly owned subsidiary of Media Source, Inc. No redistribution permitted.
Review by Kirkus Book Review
Prospects for better treatments for Parkinson's disease are the hope that lies at the end of this well-researched history and overview of the current state of research. Palfreman (Emeritus, Broadcast Journalism/Univ. of Oregon; co-author: The Case of the Frozen Addicts, 1996, etc.) brings his skill as a science writer and a deep personal commitment to an initially dark narrative. A generation ago, L-dopa was the breakthrough drug that would supply dopamine, the neurotransmitter no longer available from diseased brain cells, to neurons in movement control centers. Thus it would stop the tremors, falls, and other signs of Parkinson'sexcept when it didn't. L-dopa is notoriously difficult to deliver to the brain, and when it arrives, its release fluctuates, producing on-again, off-again effects. So the race was on to protect, revive, or transplant new cells to replace the dying ones. None of these approaches really worked, writes the author, probably because by the time movement symptoms appear, most of the dopamine cells are gone. In that sense, the tremors are only the tip of the iceberg. Among Parkinson's "prodromal" symptoms are constipation, loss of the sense of smell, sleep disorders, anxiety, and depression. Moreover, Parkinson's comes in many varieties, with different ages of onset and different rates of progression. Fortunately, there are promising developments on the horizone.g., the chance discovery that a particular phage can invade and devour the misfolded proteins in brain cells, restoring function. A small company has now developed a phage-derived protein that forms the key to opening the cells, and they are planning human trials. Other developments include new forms of L-dopa to ensure stable amounts and sustained delivery and possible exploitation of the placebo effect, which has been shown to stimulate dopamine release from other brain systems. In this illuminating book, Palfreman reminds patients that exercise and a positive attitude help, and he urges them to participate in clinical trials and take to task drug companies reluctant to initiate huge trials for what they dismiss as a non-life-threatening disease. Just ask Michael J. Fox. Copyright Kirkus Reviews, used with permission.
Copyright (c) Kirkus Reviews, used with permission.
